Kura Oncology Positioned for Growth with Promising Menin Inhibitor Ziftomenib Amidst Competitor Challenges
Leerink Partners analyst Jonathan Chang has maintained their bullish stance on KURA stock, giving a Buy rating on November 12. Jonathan ...